Estimation of individual beneficial and adverse effects of intensive glucose control for patients with type 2 diabetes

Joep van der Leeuw, Frank L J Visseren, Mark Woodward, Yolanda van der Graaf, Diederick E. Grobbee, Stephen Harrap, Simon Heller, Giuseppe Mancia, Michel Marre, Neil Poulter, Sophia Zoungas, John Chalmers

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Aims/hypothesis: Intensive glucose control reduces the risk of vascular complications while increasing the risk of severe hypoglycaemia at a group level. We sought to estimate individual beneficial and adverse effects of intensive glucose control in patients with type 2 diabetes. Methods: We performed a post hoc analysis of the Action in Diabetes and Vascular Disease: Preterax and Diamicron MR Controlled Evaluation (ADVANCE) trial, a randomised controlled trial evaluating standard vs intensive glucose control (HbA1c target ≤6.5% [48 mmol/mol]). In 11,140 participants, we estimated the individual 5 year absolute risk reduction (ARR) for the composite outcome of major micro- and macrovascular events and absolute risk increase (ARI) for severe hypoglycaemia for intensive vs standard glucose control. Predictions were based on competing risks models including clinical characteristics and randomised treatment. Results: Based on these models, 76% of patients had a substantial estimated 5 year ARR for major vascular events (>1%, 5 year number-needed-to-benefit [NNTB5] <100) and 1% had a small ARR (<0.5%, NNTB5 >200). Similarly, 36% of patients had a substantial estimated ARI for severe hypoglycaemia (5 year number-needed-to-harm [NNTH5] <100) and 29% had a small ARI (NNTH5 >200). When assigning similar or half the weight to severe hypoglycaemia compared with a major vascular event, net benefit was positive in 85% or 99% of patients, respectively. Limiting intensive treatment to the 85% patient subgroup had no significant effect on the overall incidence of major vascular events and severe hypoglycaemia compared with treating all patients. Conclusions/interpretation: Taking account of the effects of intensive glucose control on major micro- and macrovascular events and severe hypoglycaemia for individual patients, the estimated net benefit was positive in the majority of the participants in the ADVANCE trial. The estimated individual effects can inform treatment decisions once individual weights assigned to positive and adverse effects have been specified. Trial registration:: ClinicalTrials.gov NCT00145925

Original languageEnglish
Pages (from-to)1-10
Number of pages10
JournalDiabetologia
DOIs
Publication statusAccepted/In press - Sep 1 2016

Fingerprint

Type 2 Diabetes Mellitus
Hypoglycemia
Glucose
Blood Vessels
Numbers Needed To Treat
perindopril drug combination indapamide
Gliclazide
Weights and Measures
Vascular Diseases
Therapeutics
Randomized Controlled Trials
Incidence

Keywords

  • Glycaemic target
  • Hypoglycaemia
  • Net benefit
  • Personalised medicine
  • Type 2 diabetes
  • Vascular complications

ASJC Scopus subject areas

  • Internal Medicine
  • Endocrinology, Diabetes and Metabolism
  • Medicine(all)

Cite this

van der Leeuw, J., Visseren, F. L. J., Woodward, M., van der Graaf, Y., Grobbee, D. E., Harrap, S., ... Chalmers, J. (Accepted/In press). Estimation of individual beneficial and adverse effects of intensive glucose control for patients with type 2 diabetes. Diabetologia, 1-10. https://doi.org/10.1007/s00125-016-4082-5

Estimation of individual beneficial and adverse effects of intensive glucose control for patients with type 2 diabetes. / van der Leeuw, Joep; Visseren, Frank L J; Woodward, Mark; van der Graaf, Yolanda; Grobbee, Diederick E.; Harrap, Stephen; Heller, Simon; Mancia, Giuseppe; Marre, Michel; Poulter, Neil; Zoungas, Sophia; Chalmers, John.

In: Diabetologia, 01.09.2016, p. 1-10.

Research output: Contribution to journalArticle

van der Leeuw, J, Visseren, FLJ, Woodward, M, van der Graaf, Y, Grobbee, DE, Harrap, S, Heller, S, Mancia, G, Marre, M, Poulter, N, Zoungas, S & Chalmers, J 2016, 'Estimation of individual beneficial and adverse effects of intensive glucose control for patients with type 2 diabetes', Diabetologia, pp. 1-10. https://doi.org/10.1007/s00125-016-4082-5
van der Leeuw, Joep ; Visseren, Frank L J ; Woodward, Mark ; van der Graaf, Yolanda ; Grobbee, Diederick E. ; Harrap, Stephen ; Heller, Simon ; Mancia, Giuseppe ; Marre, Michel ; Poulter, Neil ; Zoungas, Sophia ; Chalmers, John. / Estimation of individual beneficial and adverse effects of intensive glucose control for patients with type 2 diabetes. In: Diabetologia. 2016 ; pp. 1-10.
@article{1ddb01aace72457a8fde29546fae0783,
title = "Estimation of individual beneficial and adverse effects of intensive glucose control for patients with type 2 diabetes",
abstract = "Aims/hypothesis: Intensive glucose control reduces the risk of vascular complications while increasing the risk of severe hypoglycaemia at a group level. We sought to estimate individual beneficial and adverse effects of intensive glucose control in patients with type 2 diabetes. Methods: We performed a post hoc analysis of the Action in Diabetes and Vascular Disease: Preterax and Diamicron MR Controlled Evaluation (ADVANCE) trial, a randomised controlled trial evaluating standard vs intensive glucose control (HbA1c target ≤6.5{\%} [48 mmol/mol]). In 11,140 participants, we estimated the individual 5 year absolute risk reduction (ARR) for the composite outcome of major micro- and macrovascular events and absolute risk increase (ARI) for severe hypoglycaemia for intensive vs standard glucose control. Predictions were based on competing risks models including clinical characteristics and randomised treatment. Results: Based on these models, 76{\%} of patients had a substantial estimated 5 year ARR for major vascular events (>1{\%}, 5 year number-needed-to-benefit [NNTB5] <100) and 1{\%} had a small ARR (<0.5{\%}, NNTB5 >200). Similarly, 36{\%} of patients had a substantial estimated ARI for severe hypoglycaemia (5 year number-needed-to-harm [NNTH5] <100) and 29{\%} had a small ARI (NNTH5 >200). When assigning similar or half the weight to severe hypoglycaemia compared with a major vascular event, net benefit was positive in 85{\%} or 99{\%} of patients, respectively. Limiting intensive treatment to the 85{\%} patient subgroup had no significant effect on the overall incidence of major vascular events and severe hypoglycaemia compared with treating all patients. Conclusions/interpretation: Taking account of the effects of intensive glucose control on major micro- and macrovascular events and severe hypoglycaemia for individual patients, the estimated net benefit was positive in the majority of the participants in the ADVANCE trial. The estimated individual effects can inform treatment decisions once individual weights assigned to positive and adverse effects have been specified. Trial registration:: ClinicalTrials.gov NCT00145925",
keywords = "Glycaemic target, Hypoglycaemia, Net benefit, Personalised medicine, Type 2 diabetes, Vascular complications",
author = "{van der Leeuw}, Joep and Visseren, {Frank L J} and Mark Woodward and {van der Graaf}, Yolanda and Grobbee, {Diederick E.} and Stephen Harrap and Simon Heller and Giuseppe Mancia and Michel Marre and Neil Poulter and Sophia Zoungas and John Chalmers",
year = "2016",
month = "9",
day = "1",
doi = "10.1007/s00125-016-4082-5",
language = "English",
pages = "1--10",
journal = "Diabetologia",
issn = "0012-186X",
publisher = "Springer Verlag",

}

TY - JOUR

T1 - Estimation of individual beneficial and adverse effects of intensive glucose control for patients with type 2 diabetes

AU - van der Leeuw, Joep

AU - Visseren, Frank L J

AU - Woodward, Mark

AU - van der Graaf, Yolanda

AU - Grobbee, Diederick E.

AU - Harrap, Stephen

AU - Heller, Simon

AU - Mancia, Giuseppe

AU - Marre, Michel

AU - Poulter, Neil

AU - Zoungas, Sophia

AU - Chalmers, John

PY - 2016/9/1

Y1 - 2016/9/1

N2 - Aims/hypothesis: Intensive glucose control reduces the risk of vascular complications while increasing the risk of severe hypoglycaemia at a group level. We sought to estimate individual beneficial and adverse effects of intensive glucose control in patients with type 2 diabetes. Methods: We performed a post hoc analysis of the Action in Diabetes and Vascular Disease: Preterax and Diamicron MR Controlled Evaluation (ADVANCE) trial, a randomised controlled trial evaluating standard vs intensive glucose control (HbA1c target ≤6.5% [48 mmol/mol]). In 11,140 participants, we estimated the individual 5 year absolute risk reduction (ARR) for the composite outcome of major micro- and macrovascular events and absolute risk increase (ARI) for severe hypoglycaemia for intensive vs standard glucose control. Predictions were based on competing risks models including clinical characteristics and randomised treatment. Results: Based on these models, 76% of patients had a substantial estimated 5 year ARR for major vascular events (>1%, 5 year number-needed-to-benefit [NNTB5] <100) and 1% had a small ARR (<0.5%, NNTB5 >200). Similarly, 36% of patients had a substantial estimated ARI for severe hypoglycaemia (5 year number-needed-to-harm [NNTH5] <100) and 29% had a small ARI (NNTH5 >200). When assigning similar or half the weight to severe hypoglycaemia compared with a major vascular event, net benefit was positive in 85% or 99% of patients, respectively. Limiting intensive treatment to the 85% patient subgroup had no significant effect on the overall incidence of major vascular events and severe hypoglycaemia compared with treating all patients. Conclusions/interpretation: Taking account of the effects of intensive glucose control on major micro- and macrovascular events and severe hypoglycaemia for individual patients, the estimated net benefit was positive in the majority of the participants in the ADVANCE trial. The estimated individual effects can inform treatment decisions once individual weights assigned to positive and adverse effects have been specified. Trial registration:: ClinicalTrials.gov NCT00145925

AB - Aims/hypothesis: Intensive glucose control reduces the risk of vascular complications while increasing the risk of severe hypoglycaemia at a group level. We sought to estimate individual beneficial and adverse effects of intensive glucose control in patients with type 2 diabetes. Methods: We performed a post hoc analysis of the Action in Diabetes and Vascular Disease: Preterax and Diamicron MR Controlled Evaluation (ADVANCE) trial, a randomised controlled trial evaluating standard vs intensive glucose control (HbA1c target ≤6.5% [48 mmol/mol]). In 11,140 participants, we estimated the individual 5 year absolute risk reduction (ARR) for the composite outcome of major micro- and macrovascular events and absolute risk increase (ARI) for severe hypoglycaemia for intensive vs standard glucose control. Predictions were based on competing risks models including clinical characteristics and randomised treatment. Results: Based on these models, 76% of patients had a substantial estimated 5 year ARR for major vascular events (>1%, 5 year number-needed-to-benefit [NNTB5] <100) and 1% had a small ARR (<0.5%, NNTB5 >200). Similarly, 36% of patients had a substantial estimated ARI for severe hypoglycaemia (5 year number-needed-to-harm [NNTH5] <100) and 29% had a small ARI (NNTH5 >200). When assigning similar or half the weight to severe hypoglycaemia compared with a major vascular event, net benefit was positive in 85% or 99% of patients, respectively. Limiting intensive treatment to the 85% patient subgroup had no significant effect on the overall incidence of major vascular events and severe hypoglycaemia compared with treating all patients. Conclusions/interpretation: Taking account of the effects of intensive glucose control on major micro- and macrovascular events and severe hypoglycaemia for individual patients, the estimated net benefit was positive in the majority of the participants in the ADVANCE trial. The estimated individual effects can inform treatment decisions once individual weights assigned to positive and adverse effects have been specified. Trial registration:: ClinicalTrials.gov NCT00145925

KW - Glycaemic target

KW - Hypoglycaemia

KW - Net benefit

KW - Personalised medicine

KW - Type 2 diabetes

KW - Vascular complications

UR - http://www.scopus.com/inward/record.url?scp=84984856925&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84984856925&partnerID=8YFLogxK

U2 - 10.1007/s00125-016-4082-5

DO - 10.1007/s00125-016-4082-5

M3 - Article

SP - 1

EP - 10

JO - Diabetologia

JF - Diabetologia

SN - 0012-186X

ER -